Evidence map›Paper›PMID 38778379›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

Icaritin-curcumol activates CD8

Wenjing Xu, Yingqiu Li, Lumei Liu, Jing Xie, Zongren Hu, Shida Kuang, Xinying Fu, Bonan Li, Tiansong Sun, Congxu Zhu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenjing Xu *Department of Dermatology, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, 410021, China.
Yingqiu Li *Medical School, Hunan University of Chinese Medicine, Changsha, 410208, China.
Lumei LiuSchool of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, 410208, China.
Jing XieSchool of Traditional Chinese Medicine, Hunan University of Medicine, No. 492 Jinxi South Road, Huaihua, 418000, China.
Zongren HuSchool of Traditional Chinese Medicine, Hunan University of Medicine, No. 492 Jinxi South Road, Huaihua, 418000, China.
Shida KuangAndrology Laboratory, Hunan University of Chinese Medicine, Changsha, 410208, China.
Xinying FuAndrology Laboratory, Hunan University of Chinese Medicine, Changsha, 410208, China.
Bonan LiSchool of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, 410208, China.
Tiansong SunSchool of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, 410208, China.
Congxu ZhuSchool of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, 410208, China.
Qinghu HeAndrology Laboratory, Hunan University of Chinese Medicine, Changsha, 410208, China. qinghu_he3418@hnucm.edu.cn.
Wen ShengSchool of Traditional Chinese Medicine, Hunan University of Medicine, No. 492 Jinxi South Road, Huaihua, 418000, China. shengwendoctor@hnucm.edu.cn.

Funding

Changsha Natural Science Foundation kq2208204Excellent Youth Project of Hunan University of Chinese Medicine Z2023XJYQ05Excellent Youth Project of Scientific Research Program of Hunan Education Department 22B0370Hunan Provincial Hygiene and Health Commission Health Research Project W20243165Natural Science Foundation of Hunan Province 2023JJ40511Project of Traditional Chinese Medicine Administration of Hunan Province B2023034
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) incidence and mortality rates are rising. Our previous research has shown that the combination of icariin (ICA) and curcumol (CUR) induced autophagy and ferroptosis in PCa cells, and altered lipid metabolism. We aimed to further explore the effects of the combination of ICA and CUR on gut microbiota, metabolism, and immunity in PCa.

methodsA mouse subcutaneous RM-1 cell tumor model was established. 16 S rRNA sequencing was performed to detect changes in fecal gut microbiota. SCFAs in mouse feces, and the effect of ICA-CUR on T-cell immunity, IGFBP2, and DNMT1 were examined. Fecal microbiota transplantation (FMT) was conducted to explore the mechanism of ICA-CUR. Si-IGFBP2 and si/oe-DNMT1 were transfected into RM-1 and DU145 cells, and the cells were treated with ICA-CUR to investigate the mechanism of ICA-CUR on PCa development.

resultsAfter treatment with ICA-CUR, there was a decrease in tumor volume and weight, accompanied by changes in gut microbiota. ICA-CUR affected SCFAs and DNMT1/IGFBP2/EGFR/STAT3/PD-L1 pathway. ICA-CUR increased the positive rates of CD3

conclusionsICA-CUR mediates the interaction between gut microbiota and the DNMT1/IGFBP2 axis to inhibit the progression of PCa by regulating immune response and metabolism, suggesting a potential therapeutic strategy for PCa.

Indexed as

CD8-Positive T-LymphocytesDNA (Cytosine-5-)-Methyltransferase 1Gastrointestinal MicrobiomeProstatic NeoplasmsAnimalsDisease Models, AnimalFlavonoidsHumansInsulin-Like Growth Factor Binding Protein 2MaleMiceDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanDnmt1 protein, mouseFlavonoidsIGFBP2 protein, humanInsulin-Like Growth Factor Binding Protein 2Gut microbiotaIcariin-curcumolMetabolismProstate cancerTumor immune microenvironment

Identifiers

PMID38778379
PMCPMC11112810

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.